Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZIC5-targeting siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
ZIC5-targeting siRNA is an experimental RNA interference (RNAi) therapeutic designed to specifically silence the expression of the Zic family member 5 (ZIC5) gene. ZIC5 is a member of the ZIC family of zinc finger transcription factors and has been identified as a key driver of cell survival and chemoresistance in pancreatic ductal adenocarcinoma (PDAC). The siRNA functions by inducing the sequence-specific degradation of ZIC5 mRNA, leading to a reduction in ZIC5 protein levels. This downregulation subsequently inhibits the expression of its direct downstream target, RIO kinase 3 (RIOK3), which is critical for the survival of pancreatic cancer cells. Preclinical studies have demonstrated that systemic administration of ZIC5-targeting siRNA can significantly reduce tumor volume and sensitize PDAC cells to gemcitabine treatment.
- Other names
- small interfering RNA targeting ZIC5ZIC5 siRNAZIC-5 siRNAZIC 5 siRNAsiRNA-ZIC5siRNA-ZIC-5siRNA-ZIC 5
02
Targets
ZIC5
Beyond the preview
Go deeper on ZIC5-targeting siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZIC5-targeting siRNA.